Background: Endocan is associated with endothelial dysfunction. In peritoneal dialysis (PD) patients, cardiovascular disease is a common cause of mortality. We examined the relationship between serum endocan level and clinical outcome of PD patients. Methods: We recruited 193 new PD patients (118 males, mean age 58.8 ± 11.6 years). Serum endocan levels were determined and stratified into tertile 1 (lowest) to 3 (highest). Nutritional status, arterial pulse wave velocity (PWV) and serum C-reactive protein (CRP) levels were measured. The patients were followed for at least 4 years for clinical outcomes. Results: For the whole cohort, patients with higher serum endocan levels had lower serum albumin and subjective global assessment score, higher carotid-femoral PWV, and higher serum CRP. For patients with suboptimal blood pressure (BP) control, cardiovascular event-free survival was 95.0, 95.5, and 78.5% for tertiles 1, 2, and 3 at 60 months respectively (p = 0.019). Multivariate Cox regression analysis showed that serum endocan level was an independent predictor of cardiovascular event-free survival. No association with cardiovascular event-free survival was found for patients with adequate BP control (95.0, 92.3, and 100% for tertile 1, 2, and 3 at 60 months, respectively, p = 0.6). Conclusions: Higher serum endocan level is associated with unfavourable nutritional, arterial and inflammatory conditions in PD patients. In patients with suboptimal BP control, higher serum endocan is also associated with worse cardiovascular outcome.
arterial pulse wave velocity (PWV), bioimpedance spectroscopy, dialysis adequacy, and nutritional assessment were performed around 4 weeks after starting dialysis. Blood pressure (BP) was measured at every clinic visit. Inadequate BP control was defined as average systolic BP above 140 mm Hg, or diastolic BP above 90 mm Hg.
Serum Endocan Level
Serum samples were stored immediately at -80 ° C after collection until testing by the Human endothelial cell-specific molecule-1 ELISA kits (Endocan; Abcam, Cambridge, UK) according to the manufacturer's instruction. The limit of detection of the assay was 10 pg/mL. The intra-and inter-assay coefficient of variations was 4.4 and 5.3% respectively.
Study of Peritoneal Transport
Standard peritoneal permeability test was performed by the method of Twardowski and has been described previously [31] . A 4-h dwell study was carried out with 2 L of dextrose 2.5% dialysis fluid (Dianeal, Baxter-Travenol, Deerfield, IL, USA). Dialysate-to-plasma ratios of creatinine (D/P) at 4 h were calculated after correction of glucose interference. Mass transfer area coefficients of creatinine normalized for body surface area was calculated by a standard formula [32] . The simplified dialysis adequacy and transport test [33] and PD effluent protein level [34] were determined at 0, 12, and 24 months for the monitoring of peritoneal transport function of small and large molecules respectively.
Dialysis Adequacy, Nutrition and Inflammation Markers
The method of dialysis adequacy assessment has been described previously [35] . In order to calculate total Kt/V, 24-h urine and dialysate collection was performed. Nutritional status was represented by the serum albumin level, subjective global assessment (SGA), comprehensive malnutrition-inflammation score (MIS), and normalized protein nitrogen appearance (NPNA). For SGA, the 4-item 7-point scoring system validated in PD patients was used [36] . The calculation of MIS was described previously [37] . NPNA was calculated by the modified Bergstrom's formula [38] . Serum CRP was measured by a commercially available ultra-sensitive assay (Roche Diagnostics GmbH, Mannheim, Germany).
PWV Study
Arterial PWV was measured by an automatic computerized recorder and analyzed using the Complior ® SP program (Artech Medical, France). The method of PWV measurement has been described previously [39] . In this study, we measured both the carotid-femoral PWV (CF-PWV) and carotid-radial PWV (CR-PWV).
Clinical Follow-Up
All patients were followed for at least 4 years. The clinical management and dialysis regimen were decided by individual nephrologist and not affected by the study. Primary outcome measures of this study included patient survival, technique survival, peritonitis-free survival, cardiovascular event-free survival, and hospitalization within 1 year of PD. Censoring events for patient survival analysis included transfer to long-term hemodialysis, kidney transplant, recovery of renal function, loss to follow-up, or transfer to other dialysis centers. Technique survival was defined as being alive and remaining on PD. A cardiovascular event was defined as a fatal or non-fatal myocardial infarction or stroke, hospital admission for unstable angina, coronary intervention, transient ischemic attack, or peripheral vascular disease that required surgical reconstruction or amputation. 
Statistical Analysis
Statistical analysis was performed using SPSS for Windows software version 22 (SPSS Inc., Chicago, IL, USA). Data were expressed as mean ± SD unless specified otherwise. Comparisons between groups were performed by chi-square test, student t test, one way analysis of variance or Kruskal-Wallis test as appropriate. Correlation between continuous parameters was explored by the Spearman's rank correlation coefficient. Since serum endocan levels were highly skewed, they were log-transformed for survival model construction and grouped to tertile 1-3, with increasing endocan levels, for other analysis. Kaplan-Meier analysis and the log rank test were used to explore the effect of endocan level tertiles on the clinical outcome. Multivariate Cox regression analysis was then used to determine independent predictors of clinical outcome. In addition to serum endocan level, we also added baseline residual glomerular filtration rate, total Kt/V, serum albumin, Charlson's comorbidity score, sex, age, body mass index, diabetic status, systolic and diastolic BP into the Cox proportional hazard model. Backward stepwise analysis was applied to remove insignificant variables. A p value below 0.05 was considered statistically significant. All probabilities were two-tailed.
Results
We recruited 193 new PD patients. Their demographic and baseline clinical information are summarized in Table 1 . All baseline clinical and laboratory parameters were comparable among the 3 tertile groups, except a slight difference in body weight and body mass index. 
Relation with Baseline Assessment
Peritoneal transport characteristics, arterial PWV, bioimpedance spectroscopy, dialysis adequacy, and nutritional status are shown in Table 2 . Serum endocan level tertile 3 had significantly lower serum albumin level than tertiles 2 and 1 (Fig. 1a ). There was a modest but significant correlation between serum albumin and endocan level (Spearman's r = -0.175, p = 0.017). Serum endocan level also had modest correlation with NPNA (r = -0.150, p = 0.042). There was a significant progressive decrease in SGA score (5.5 ± 0.8, 5.4 ± 0.9, and 5.1 ± 0.8 respectively, p = 0.045) and increase in MIS (6.1 ± 3.2, 6.4 ± 3.7 and 7.7 ± 3.3 respectively, p = 0.026) from endocan level tertile 1-3. On the other hand, serum endocan level did not correlate with the overhydration volume, ECW:ICW ratio, or lean tissue mass as determined by bioimpedance spectroscopy (details not shown).
Serum endocan level tertile 1 had significantly lower CF-PWV than tertiles 2 and 3 ( Fig. 1b ). On the other hand, there was no significant difference in CR-PWV between serum endocan level tertiles 1, 2, and 3 (10.3 ± 2.1, 10.4 ± 1.6, and 10.7 ± 1.6 m/s respectively, p = 0.3). There was a significant increase in serum CRP level from endocan level tertile 1-3 ( Fig. 1c ). Serum endocan also correlated significantly with serum CRP level (r = 0.363, p < 0.001).
Relation with Clinical Outcome
The average follow-up was 40.1 ± 18.0 months. During the follow-up period, 86 patients died. The causes of death were sudden cardiac death (4 cases), coronary heart disease (21 cases), cerebrovascular accident (8 cases), malignancy (5 cases), peritonitis (4 cases), non-peritonitis infections (38 cases), termination of dialysis (4 cases), and other reasons (2 cases). At the same period, 15 patients had kidney transplantation, 16 were converted to hemodialysis, 3 were transferred to another center, and 1 had recovered renal function.
At 60 months, patient survival was 63.1, 30.1, and 46.4% for serum endocan level tertiles 1, 2, and 3 respectively (log rank test, p = 0.034; Fig. 2a ). However, serum endocan level tertile was not an independent predictor of patient survival after adjusting for clinical confounders by multivariate Cox regression analysis. In this model, only Charlson's comorbidity score and serum albumin level were independent predictors of patient survival (Table 3a) . Similarly, technique survival at 60 months was 48.8, 21.2, and 36.0% for serum endocan level tertiles 1, 2, and 3 respectively (p = 0.033; Fig. 2b ). Multivariate Cox regression analysis showed that Charlson's comorbidity score was the only independent predictor of technique survival (Table 3b ). There was no significant difference in peritonitis-free survival (27.1, 32.1, and 30.8% at 60 months for tertile 1, 2, and 3 respectively, p = 0.2) or cardio- vascular event-free survival (95.0, 94.8, and 84.5% at 60 months for tertile 1, 2, and 3 respectively, p = 0.09). There was no significant difference in the number of hospital admission or duration of hospital stay in 1 year between the serum endocan tertile groups (Table 4) .
Interaction with BP Control
Of the 193 patients, 94 had suboptimal BP control. Their baseline demographic and clinical parameters were not significantly different from the 99 patients with satisfactory BP (details not shown). Although serum endocan level was not associated with cardiovascular event-free survival of the entire cohort, there was a significant interaction between serum endocan levels and BP control on cardiovascular event-free survival (p of interaction = 0.003). For patients with suboptimal BP control, cardiovascular event-free survival was 95.0, 95.5, and 78.5% for serum endocan level tertiles 1, 2, and 3 respectively (p = 0.019). By multivariate Cox regression analysis, serum endocan level, Charlson's comorbidity score, and age were independent predictors of cardiovascular event-free survival in patients with suboptimal BP control (Table 3c ). In contrast, cardiovascular event-free survival of patients with adequate BP control was similar between serum endocan level tertiles 1, 2, and 3 (95.0, 92.3, and 100% for tertile 1, 2, and 3 at 60 months, respectively, p = 0.6).
Relation with Change in PWV and Peritoneal Transport
Arterial PWV was repeated in 73 patients 1 year after PD. There was a significant difference in the change in CF-PWV after 1 year between serum endocan tertile groups, with a trend of increase in CF-PWV for tertile 3 (one way analysis of variance, p = 0.037; Fig. 3 ). On the other hand, there was no significant difference in change in CR-PWV over 1 year between serum endocan level tertiles (details not shown). There was also no significant difference in peritoneal transport characteristics, as determined by dialysis adequacy and transport test and PD effluent protein level, between serum endocan tertile groups during the study period ( Table 5 ).
Discussion
In the present study, we found that serum endocan levels correlated with the nutritional status of Chinese PD patients. Higher endocan tertile groups were associated with lower SGA and higher MIS, and serum albumin level negatively correlated with serum endocan levels. In our cohort, the average serum albumin level was below 38 g/L, indicating a high prevalence of background malnutrition. However, the serum albumin level was the lowest in endocan tertile 3, implying that malnutrition is particularly severe in this group. This observation may be partly explained by the inverse correlation between serum endocan and NPNA, which is an indicator of dietary protein intake and appetite. However, the correlation between serum endocan and NPNA was only modest. Other mechanisms may also exist to account for the relation between serum endocan level and malnutrition.
We observed a close correlation between serum endocan and CRP levels, suggesting that endocan may be related to systemic inflammation. Our observation is consistent with reports by other groups [18, 26] . As a cross-sectional study, it is impossible to distinguish whether endocan is the cause or effect (or a co-incidental bystander) of inflammation by our result, and, because of the limitation of our study design and measurement at a single time point, we could not determine the role of repeated serial endocan level measurement for the monitoring of systemic inflammation. Nonetheless, recent literature suggested that endocan directly regulated vascular inflammation, partly by modulating leukocyte diapedesis [15, 40] .
In our whole cohort, patients with higher serum endocan levels also had higher CF-PWV, which is a marker of arterial stiffness [41] and is associated with fluid overload, cardiovascular events, cerebrovascular events, hospitalization, and mortality in PD patients [42] [43] [44] [45] . Since endocan had been reported to have effects on carotid intima media thickness and FMV [18, 26] , it is not surprising to observe a similar relation with arterial stiffness. Unfortunately, we did not directly measure markers of endothelial dysfunction, such as flow-mediated dilatation of arteries, in our cohort, with which we could explore the correlation with serum endocan level. Taken together, endocan appears to be related to both structural and functional changes of the vascular system of CKD patients.
Yilmaz et al. [18] reported that higher serum endocan was associated with worse patient survival in CKD patients. However, serum endocan level was not a predictor of survival in our study. The reason of the discrepancy is not known but is probably related to the difference in the severity of renal failure. In our study, all patients had ESRD and likely advanced background atherosclerosis. Further studies are needed to clarify the prognostic value of serum endocan in dialysis patients. In this study, we found that patients in tertile 2 seemed to have worse survival than those in tertile 3 endocan levels, but post hoc comparison of the 2 group showed no significant difference. Our observation probably indicates that only patients with tertile 1 endocrine level enjoyed a better survival. More importantly, we found a significant interaction between serum endocan levels and BP control on cardiovascular event-free survival. This observation has not been noted in previous studies, and the interaction between endocan and BP on CVD is complicated. Serum endocan level was higher in hypertensive patients than normotensive controls [21, 22] . Endocan is an initiator of endothelial dysfunction and probably contributes to the development of hypertension [18, 25, 26, 46] . On the other hand, we found a significant correlation between serum endocan and CRP levels, indicating that serum endocan level is a marker of systematic inflammation, which may lead to the development of CVD independent of BP control. In this study, our assessment of longitudinal change in peritoneal function may not be comprehensive. Theoretically, it would be interesting to obtain peritoneal biopsy from patients with membrane failure and determine the correlation between serum endocan level and submesothelial vessel number or thickness of fibrotic layer. However, peritoneal biopsy is rarely performed in real-life clinical practice for patients with membrane failure.
There are several inadequacies of our present study. First, we measured serum endocan levels only once 4 weeks after starting dialysis. Serial monitoring of serum endocan levels may yield more prognostic information. The serum endocan levels in our study are similar to previous reports [18, 45] . In this study, we did not measure endocan level in PD effluent, but a recent study by another group showed that endocan levels in PD effluent are usually substantially lower than those in serum [47] . Because of the limitation in our study design, we focused on the clinical assessment of vascular function and did not measure serum or dialysate levels of vascular endothelial growth factor simultaneously. Previous studies showed that endocan expression is regulated by vascular endothelial growth factor, which also inversely affected serum albumin levels [19, 27, 48, 49] . Similarly, we did not measure serum ICAM-1 and VCAM-1 levels, or other assessment of vascular function, which limits our understanding on the relation between endocan and endothelial dysfunction.
In conclusion, serum endocan levels correlate with CF-PWV and serum CRP levels, and inversely with serum albumin, suggesting that endocan is related to the nutrition and systemic inflammatory status, as well as arterial stiffness of PD patients. In PD patients with unsatisfactory BP control, high serum endocan levels are associated with a worse cardiovascular event-free survival. Our findings highlight the complex interactions between endocan, nutrition, arterial stiffness, systemic inflammation, and BP control on the clinical outcome, especially cardiovascular events, in PD patients. 
